Coronary stents case study

Thrombotic thrombocytopenic purpura has been repeatedly reported (6). The incidence has been estimated at 1 in 1600 (based on the observation of 5 cases out of a total of 7842 patients studied after coronary stent placements) (13). This rare adverse reaction is generally observed after a short exposure period of about 3-8 weeks. The clinical features are generally indistinguishable from those of idiopathic thrombotic thrombocytopenic purpura (14). The pathogenesis is unknown. Platelet antibodies were found in one patient, suggesting an immunologic mechanism (6). The outcome appears to be favorable in comparison to that of idiopathic thrombotic thrombocytopenic purpura, but several authors have reported cases in which death resulted (15,16). Early diagnosis and the rapid institution of plasmapheresis provide the best hope of complete recovery. 

Kwok OH, Chow WH, Law TC, et al. First human experience with angiopeptin-eluting stent a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Catheter Cardiovasc Interv2005 66(4) 54l-546. Nakamura M, Wada M, Hara H, et al. Angiographic and clinical outcomes of a pharmacokinetic study of sirolimus-eluting stents lesson from restenosis cases. Circ J 2005 69(10) ... 

---